This company has been acquired
Agile Therapeutics Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 0/6
Agile Therapeutics has been growing earnings at an average annual rate of 7.8%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 66.5% per year.
Anahtar bilgiler
7.8%
Kazanç büyüme oranı
35.0%
EPS büyüme oranı
Pharmaceuticals Sektör Büyümesi | 6.0% |
Gelir büyüme oranı | 66.5% |
Özkaynak getirisi | n/a |
Net Marj | -73.5% |
Son Kazanç Güncellemesi | 30 Jun 2024 |
Yakın geçmiş performans güncellemeleri
Recent updates
Agile appoints chief commercial officer from within ranks amid leadership revamp
Oct 10Agile gains as H.C. Wainwright sees 630% upside potential
Jul 11Agile Therapeutics prices $24M upsized stock offering
Jul 01Agile Therapeutics: Twirla's Lackluster Launch Forces Me To Change My Strategy
Apr 04Agile Therapeutics: Bullish On Capitulation And Max Pain
Oct 19Agile Therapeutics: Another Quarter Of Progress And Another Opportunity To Buy
Jul 30Agile Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation
May 06How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Did Insiders Buy, In The Last Year?
Feb 25Agile Therapeutics issues cash projection at JP Morgan healthcare conference
Jan 14Assessing Agile Therapeutics
Jan 10How Many Agile Therapeutics, Inc. (NASDAQ:AGRX) Shares Do Institutions Own?
Jan 04Agile Therapeutics announces peer-reviewed publication of late-stage study for Twirla contraception patch
Nov 30Agile Therapeutics EPS in-line
Nov 12Gelir ve Gider Dağılımı
Agile Therapeutics nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
---|---|---|---|---|
30 Jun 24 | 22 | -16 | 25 | 2 |
31 Mar 24 | 21 | -8 | 27 | 2 |
31 Dec 23 | 20 | -14 | 28 | 2 |
30 Sep 23 | 20 | -14 | 32 | 3 |
30 Jun 23 | 16 | -19 | 33 | 3 |
31 Mar 23 | 13 | -20 | 35 | 3 |
31 Dec 22 | 11 | -25 | 42 | 3 |
30 Sep 22 | 8 | -41 | 50 | 5 |
30 Jun 22 | 7 | -52 | 54 | 5 |
31 Mar 22 | 6 | -64 | 60 | 5 |
31 Dec 21 | 4 | -71 | 58 | 6 |
30 Sep 21 | 3 | -69 | 56 | 8 |
30 Jun 21 | 2 | -68 | 54 | 10 |
31 Mar 21 | 1 | -61 | 45 | 12 |
31 Dec 20 | 1 | -52 | 36 | 14 |
30 Sep 20 | 0 | -40 | 25 | 13 |
30 Jun 20 | 0 | -29 | 16 | 12 |
31 Mar 20 | 0 | -22 | 12 | 10 |
31 Dec 19 | 0 | -19 | 9 | 10 |
30 Sep 19 | 0 | -16 | 7 | 9 |
30 Jun 19 | 0 | -16 | 7 | 8 |
31 Mar 19 | 0 | -18 | 7 | 9 |
31 Dec 18 | 0 | -20 | 9 | 10 |
30 Sep 18 | 0 | -22 | 10 | 11 |
30 Jun 18 | 0 | -26 | 12 | 12 |
31 Mar 18 | 0 | -28 | 13 | 14 |
31 Dec 17 | 0 | -28 | 12 | 14 |
30 Sep 17 | 0 | -27 | 11 | 17 |
30 Jun 17 | 0 | -28 | 10 | 19 |
31 Mar 17 | 0 | -29 | 9 | 21 |
31 Dec 16 | 0 | -29 | 9 | 21 |
30 Sep 16 | 0 | -27 | 9 | 22 |
30 Jun 16 | 0 | -29 | 8 | 25 |
31 Mar 16 | 0 | -29 | 8 | 25 |
31 Dec 15 | 0 | -30 | 7 | 26 |
30 Sep 15 | 0 | -33 | 7 | 24 |
30 Jun 15 | 0 | -30 | 6 | 21 |
31 Mar 15 | 0 | -25 | 6 | 17 |
31 Dec 14 | 0 | -16 | 5 | 13 |
30 Sep 14 | 0 | -12 | 4 | 10 |
30 Jun 14 | 0 | -9 | 4 | 7 |
31 Mar 14 | 0 | -10 | 3 | 7 |
Kaliteli Kazançlar: AGRX is currently unprofitable.
Büyüyen Kar Marjı: AGRX is currently unprofitable.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: AGRX is unprofitable, but has reduced losses over the past 5 years at a rate of 7.8% per year.
Büyüme Hızlandırma: Unable to compare AGRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Kazançlar vs. Sektör: AGRX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Özkaynak Getirisi
Yüksek ROE: AGRX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.